In-vivo Bioequivalence Study of Empagliflozin/Linagliptin 25/5 mg Kharazmi Pharma Co Tablets of The Test Drug in Compared with The Reference Drug (GLYXAMBI® Tab 25/5 mg. Beohringer Ingelheim Germany) In Healthy Volunteers
In-vivo Bioequivalence Study of Linagliptin/Metformin 2.5/1000 mg FC. Tablets of The Test Drug (Kharazmi Pharma, Iran) in Compared with The Reference Drug (Jentadueto® 2.5/1000 mg, Boehringer Ingelheim, Germany) in fasting condition in healthy volunteers
In-vivo Bioequivalence Study of Empagliflozin/Metformin 5/500 mg FC. Tablets of The Test Drug (JARINOMET® 5/500 mg Tab. Kharazmi Pharma, Iran) in Compared with The Reference Drug (SYNJARDI® 5/500 mg. Boehringer Ingelheim Germany) In Iranian Healthy Volunteers
100 项与 Kharazmi Pharmaceutical Co. 相关的临床结果
0 项与 Kharazmi Pharmaceutical Co. 相关的专利(医药)
100 项与 Kharazmi Pharmaceutical Co. 相关的药物交易
100 项与 Kharazmi Pharmaceutical Co. 相关的转化医学